Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency research hub

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human) in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency

This study tests whether a weekly drip of a protein medicine can protect the lungs in adults with alpha-1 antitrypsin deficiency. Researchers want to see if two different doses can slow down lung damage and reduce severe chest flare-ups compared to a dummy treatment.